Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 12:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1129–1152 of 9,917 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Single Arm Clear all
Completed Phase 4 Interventional

Ocular Safety and Usability Study for FYB201 PFS

NCT06708624
View directory record Official record
Conditions
Age-Related Macular Degeneration, Branch Retinal Vein Occlusion with Macular Edema, Central Retinal Vein Occlusion with Macular Edema
Interventions
FYB201 0.5 mg (0.05 mL of 10 mg/mL)
Drug
Lead sponsor
Formycon AG
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
4
States / cities
Campbell, California • Long Beach, California • Hagerstown, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 27, 2024 · Synced Oct 28, 2026, 12:23 AM EDT
Completed Phase 4 Interventional

Prevention of Post-OP AFib Using Combination of CardiaMend and Amiodarone

NCT05681182
View directory record Official record
Conditions
Post Operative Atrial Fibrillation
Interventions
CardiaMend with the Addition of Amiodarone
Combination Product
Lead sponsor
WakeMed Health and Hospitals
Other
Eligibility
20 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 22, 2024 · Synced Oct 28, 2026, 12:23 AM EDT
Completed Phase 1 Interventional

Phase 1 Trial of Interleukin 12 Gene Therapy for Metastatic Pancreatic Cancer

NCT03281382
View directory record Official record
Conditions
Metastatic Pancreatic Cancer
Interventions
Ad5-yCD/mutTKSR39rep-hIL12
Biological
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Oct 28, 2026, 12:23 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

The STOP-HPV Trial 5: Single Arm Evaluation of the Bundle

NCT03609320
View directory record Official record
Conditions
Immunization, Vaccination
Interventions
The STOP-HPV Trial 5: Bundle Intervention
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
11 Years to 17 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Itasca, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 5, 2022 · Synced Oct 28, 2026, 12:23 AM EDT
Active, not recruiting Not applicable Interventional

An Investigation to Validate Speech Perception Assessment for Adult Cochlear Recipients Using a Mobile Research App

NCT06098482
View directory record Official record
Conditions
Hearing Loss
Interventions
Mobile Research App (MRA), SOC/validated delivery of the speech perception test material
Device · Other
Lead sponsor
Cochlear
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Lone Tree, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 28, 2026, 12:23 AM EDT
Terminated Phase 2 Interventional Results available

Topical Remetinostat Gel as Neoadjuvant Therapy in Patients With Squamous Cell Carcinoma (SCC)

NCT03875859
View directory record Official record
Conditions
Squamous Cell Carcinoma
Interventions
Remetinostat
Drug
Lead sponsor
Kavita Sarin
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated May 20, 2021 · Synced Oct 28, 2026, 12:23 AM EDT
Terminated Phase 3 Interventional Results available

A Study of Intravesical Qapzola (Apaziquone) as a Surgical Adjuvant in Participants Undergoing Transurethral Resection of Bladder Tumor (TURBT)

NCT03224182
View directory record Official record
Conditions
Bladder Cancer
Interventions
Qapzola, Placebo
Drug
Lead sponsor
Spectrum Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 89 Years
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 28, 2021 · Synced Oct 28, 2026, 12:23 AM EDT
Withdrawn Not applicable Interventional

Evaluation of Perforator Phase Contrast Angiography in Developing Surgery Plans for Patients With Breast Cancer Undergoing Breast Reconstruction With Free-Flap Methods After Mastectomy

NCT04063410
View directory record Official record
Conditions
Mammoplasty Patient
Interventions
Angiography, MRI-Based Angiogram, Quality-of-Life Assessment
Procedure · Other
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 18, 2024 · Synced Oct 28, 2026, 12:23 AM EDT
Terminated Phase 1 Interventional

A Study Evaluating the Drug Levels of Iplimumab Given Under the Skin Alone and in Combination With Nivolumab in Multiple Tumor Types

NCT04311710
View directory record Official record
Conditions
Tumor
Interventions
ipilimumab, nivolumab, ENHANZE (rHuPH20)
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
2
States / cities
Hartford, Connecticut • Fort Wayne, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 24, 2023 · Synced Oct 28, 2026, 12:23 AM EDT
Active, not recruiting Not applicable Interventional

Sleep for Stroke Management and Recovery Trial

NCT03812653
View directory record Official record
Conditions
Ischemic Stroke, Sleep Apnea, Sleep Apnea, Obstructive, Stroke, CPAP, Telemedicine, Home Sleep Apnea Test, Randomized Clinical Trial, Multicenter Trial
Interventions
CPAP
Device
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
3,062 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
116
States / cities
Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 94 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Oct 28, 2026, 12:23 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Emapalumab in Adult Patients With HLH

NCT03985423
View directory record Official record
Conditions
Hemophagocytic Lymphohistiocytoses
Interventions
Emapalumab-Lzsg
Drug
Lead sponsor
Swedish Orphan Biovitrum
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 6, 2023 · Synced Oct 28, 2026, 12:23 AM EDT
Terminated Phase 2 Interventional Results available

Induction Chemo Then Concurrent Chemoradiotherapy With Cetuximab in Locally Advanced Head and Neck Squamous Cell Cancer

NCT01326923
View directory record Official record
Conditions
Head and Neck Squamous Cell Cancer
Interventions
Cetuximab
Drug
Lead sponsor
Louisiana State University Health Sciences Center Shreveport
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Shreveport, Louisiana
Source: ClinicalTrials.gov public record
Updated Oct 9, 2020 · Synced Oct 28, 2026, 12:23 AM EDT
Recruiting Not applicable Interventional

Antibiotic Device for Osteomyelitis of the Extremities Pivotal Trial - Genex With Gentamicin.

NCT07270380
View directory record Official record
Conditions
Osteomyelitis
Interventions
genex with gentamicin (genex G)
Device
Lead sponsor
Biocomposites Ltd
Industry
Eligibility
18 Years and older
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
4
States / cities
San Diego, California • Indianapolis, Indiana • Baltimore, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 28, 2026, 12:23 AM EDT
Not listed Not applicable Interventional

Effect of Modified Time-restricted Feeding in Preventing Progression of Non-Alcoholic Fatty Liver Disease (NAFLD).

NCT03848390
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease
Interventions
Conventional diet, Modified Time-restricted Feeding, Physical activity, Restricted consumption of sweetened beverages
Behavioral
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
8 Years to 18 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 15, 2019 · Synced Oct 28, 2026, 12:23 AM EDT
Completed Not applicable Interventional Results available

Improving Diabetes Care Through Effective Personalized Patient Portal Interactions

NCT02953262
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
My HealtheVet Brochure, My HealtheVet Training Guide for Veterans Living with Diabetes, My HealtheVet Group Training, My HealtheVet Individual Training
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 85 Years
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
2
States / cities
Bedford, Massachusetts • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 28, 2023 · Synced Oct 28, 2026, 12:23 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Determine the Safety and Immunogenicity of Bivalent GI.1 and GII.4 Vaccines in Healthy Volunteers

NCT05626803
View directory record Official record
Conditions
Norovirus Infections
Interventions
Open label Bivalent GII.4/GI.1 high dose vaccine 2×10 to the power 11 IU/dose, Bivalent GII.4/GI.1 high dose vaccine 2×10 to the power 11 IU/dose, Bivalent GII.4/GI.1 medium dose vaccine 1×10 to the power 11 IU/dose, Placebo
Drug
Lead sponsor
Vaxart
Industry
Eligibility
18 Years to 80 Years
Enrollment
135 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
3
States / cities
Long Beach, California • Lenexa, Kansas • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 15, 2025 · Synced Oct 28, 2026, 12:23 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Study of Technology to Accelerate Research

NCT01537510
View directory record Official record
Conditions
Obesity
Interventions
STAR - Study of Technology to Accelerate Research
Behavioral
Lead sponsor
Harvard Pilgrim Health Care
Other
Eligibility
6 Years to 12 Years
Enrollment
549 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 27, 2013 · Synced Oct 28, 2026, 12:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB133 (Dapirolizumab Pegol) in Healthy Japanese and Caucasian Participants

NCT04571424
View directory record Official record
Conditions
Healthy Volunteers
Interventions
BIIB133 (Dapirolizumab pegol), Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Apr 18, 2023 · Synced Oct 28, 2026, 12:23 AM EDT
Completed Phase 2 Interventional Results available

Dupilumab for the Treatment of Moderate to Severe Chronic Hepatic Pruritus

NCT04256759
View directory record Official record
Conditions
Pruritus
Interventions
Dupilumab 300Mg Solution for Injection
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Nov 21, 2025 · Synced Oct 28, 2026, 12:23 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65

NCT01208662
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Lenalidomide, Bortezomib, Dexamethasone, Autologous Stem Cell Transplant
Drug · Procedure
Lead sponsor
Paul Richardson, MD
Other
Eligibility
18 Years to 65 Years
Enrollment
729 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2026
U.S. locations
46
States / cities
Birmingham, Alabama • Tucson, Arizona • Duarte, California + 37 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 28, 2026, 12:23 AM EDT
Recruiting Phase 1 Interventional

Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors

NCT06233942
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
BG-C9074, Tislelizumab, Bevacizumab
Drug
Lead sponsor
BeOne Medicines
Industry
Eligibility
18 Years and older
Enrollment
308 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
5
States / cities
Los Angeles, California • Aurora, Colorado • Orlando, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 28, 2026, 12:23 AM EDT
Recruiting Phase 2 Interventional

Phase 2 EL219 Versus Liposomal Amphotericin B or Voriconazole for Early Antifungal Therapy

NCT07215273
View directory record Official record
Conditions
Invasive Mould Infection
Interventions
EL219, Active Comparator- IV Antifungal (LAmB or voriconazole)
Drug
Lead sponsor
Elion Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
11
States / cities
Birmingham, Alabama • Sacramento, California • Augusta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Oct 28, 2026, 12:23 AM EDT
Completed Not applicable Interventional Results available

Design of a Dressing for Gastrostomy Buttons in Pediatric Population

NCT03142750
View directory record Official record
Conditions
Gastrostomy Complications
Interventions
Gastrostomy tube dressing
Device
Lead sponsor
University of Colorado, Denver
Other
Eligibility
31 Days to 25 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Oct 28, 2026, 12:23 AM EDT
Terminated Not applicable Interventional Results available

Auditory Brainstem Implant (ABI) in Pediatric Non-Neurofibromatosis Type 2 Subjects

NCT01864291
View directory record Official record
Conditions
Bilateral Hearing Loss for Causes Other Than Tumors
Interventions
Nucleus 24 (discontinued) and ABI541 Auditory Brainstem Implants (ABI)
Device
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
18 Months to 17 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 2, 2020 · Synced Oct 28, 2026, 12:23 AM EDT